| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $34,141,220 | 34 | 100 |
| Zimmermann Martine | director | 0 | $0 | 1 | $342,000 | $-342,000 |
| Gray Nancy Ryan | director | 0 | $0 | 1 | $619,432 | $-619,432 |
| KOZARICH JOHN W | director | 0 | $0 | 9 | $1.11M | $-1.11M |
| Sabba Stephen L | director | 0 | $0 | 3 | $1.16M | $-1.16M |
| Aryeh Jason | director | 0 | $0 | 4 | $1.93M | $-1.93M |
| LAMATTINA JOHN L | director | 0 | $0 | 3 | $2M | $-2M |
| Haas Jason | director | 0 | $0 | 2 | $3.74M | $-3.74M |
| Reardon Andrew | CLO & Secretary | 0 | $0 | 8 | $10.29M | $-10.29M |
| Espinoza Octavio | Chief Financial Officer | 0 | $0 | 4 | $13.03M | $-13.03M |
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and …
Over the last 12 months, insiders at Ligand Pharmaceuticals Incorporated have bought $0 and sold $34.14M worth of Ligand Pharmaceuticals Incorporated stock.
On average, over the past 5 years, insiders at Ligand Pharmaceuticals Incorporated have bought $461,116 and sold $12.53M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,510 shares for transaction amount of $1M was made by Davis Todd C (Chief Executive Officer) on 2025‑05‑09.
| 2026-11-02 | Sale | Aryeh Jason | director | 700 0.0037% | $320.43 | $224,298 | -2.16% | |
| 2026-10-30 | Sale | Aryeh Jason | director | 1,411 0.007% | $320.24 | $451,860 | ||
| 2026-10-02 | Sale | Reardon Andrew | CLO & Secretary | 5,000 0.025% | $304.07 | $1.52M | +1.20% | |
| 2026-09-10 | Sale | Zimmermann Martine | director | 1,200 0.0059% | $285.00 | $342,000 | +4.50% | |
| 2026-09-03 | Sale | Reardon Andrew | CLO & Secretary | 5,000 0.0246% | $286.09 | $1.43M | +3.64% | |
| 2026-08-12 | Sale | Espinoza Octavio | Chief Financial Officer | 31,641 0.1572% | $292.06 | $9.24M | +0.59% | |
| 2026-08-12 | Sale | Haas Jason | director | 7,138 0.0356% | $292.81 | $2.09M | +0.59% | |
| 2026-08-03 | Sale | Reardon Andrew | CLO & Secretary | 5,000 0.0249% | $288.99 | $1.44M | +1.01% | |
| 2026-07-01 | Sale | Reardon Andrew | CLO & Secretary | 5,000 0.025% | $313.28 | $1.57M | -4.83% | |
| 2026-06-16 | Sale | Sabba Stephen L | director | 2,145 0.0107% | $254.00 | $544,830 | +16.14% | |
| 2026-06-12 | Sale | Haas Jason | director | 6,461 0.0322% | $255.58 | $1.65M | +15.95% | |
| 2026-06-11 | Sale | Aryeh Jason | director | 4,500 0.0221% | $250.00 | $1.13M | +16.39% | |
| 2026-06-10 | Sale | Aryeh Jason | director | 500 0.0025% | $250.00 | $125,000 | +19.35% | |
| 2026-06-10 | Sale | LAMATTINA JOHN L | director | 4,591 0.0232% | $250.88 | $1.15M | +19.35% | |
| 2026-06-01 | Sale | Reardon Andrew | CLO & Secretary | 5,000 0.0247% | $227.06 | $1.14M | +28.65% | |
| 2026-05-13 | Sale | KOZARICH JOHN W | director | 1,575 0.0079% | $223.50 | $352,013 | +32.57% | |
| 2026-05-12 | Sale | KOZARICH JOHN W | director | 459 0.0023% | $224.00 | $102,816 | +32.10% | |
| 2026-05-01 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $231.80 | $108,251 | +28.05% | |
| 2026-05-01 | Sale | Reardon Andrew | CLO & Secretary | 5,000 0.0255% | $231.31 | $1.16M | +28.05% | |
| 2026-04-01 | Sale | KOZARICH JOHN W | director | 467 0.0024% | $202.23 | $94,440 | +44.07% |
| Aryeh Jason | director | 108758 0.5455% | $34.1M | 16 | 32 | +22.84% |
| KOZARICH JOHN W | director | 41786 0.2096% | $13.1M | 11 | 28 | +5.2% |
| Sabba Stephen L | director | 33629 0.1687% | $10.54M | 3 | 9 | +53.27% |
| Espinoza Octavio | Chief Financial Officer | 27696 0.1389% | $8.68M | 1 | 12 | +78.49% |
| LAMATTINA JOHN L | director | 26969 0.1353% | $8.46M | 1 | 9 | +21.17% |
| Loeb Daniel S | 2027378 10.1696% | $635.62M | 2 | 1 | <0.0001% | |
| HIGGINS JOHN L | director | 422984 2.1218% | $132.61M | 7 | 25 | +13.8% |
| FOEHR MATTHEW W | President and COO | 173354 0.8696% | $54.35M | 7 | 13 | +42.46% |
| Davis Todd C | Chief Executive Officer | 161234 0.8088% | $50.55M | 4 | 7 | +35.56% |
| BVF PARTNERS L P/IL | 130175 0.653% | $40.81M | 42 | 13 | +48.51% | |
| MEGLASSON MARTIN | V-P, Discovery Research | 102250 0.5129% | $32.06M | 4 | 1 | <0.0001% |
| KNOTT DAVID M | director | 66152 0.3318% | $20.74M | 29 | 24 | +12.82% |
| Berkman Charles S | SVP, Gen. Counsel & Secretary | 27763 0.1393% | $8.7M | 4 | 14 | +29.72% |
| Patel Sunil | director | 24524 0.123% | $7.69M | 4 | 2 | +36.15% |
| DeSilva Nishan M | VP, Finance & Strategy and CFO | 22282 0.1118% | $6.99M | 1 | 4 | +51.09% |
| Herman Melanie J | Director of Accounting | 3297 0.0165% | $1.03M | 2 | 6 | +28.8% |
Ligand Pharmaceuticals Incorporated (LGND) | $67,892,722 | 138 | 28.28% | $6.25B |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$477,065,869 | 34 | 82.05% | $6B | |
$1,801,511 | 23 | 18.58% | $8.41B |
| Increased Positions | 182 | +51.85% | 2M | +9.98% |
| Decreased Positions | 148 | -42.17% | 2M | -9.76% |
| New Positions | 69 | New | 305,687 | New |
| Sold Out Positions | 30 | Sold Out | 871,531 | Sold Out |
| Total Postitions | 385 | +9.69% | 21M | +0.22% |
| Blackrock, Inc. | $548,377.00 | 14.42% | 2.88M | -29,214 | -1% | 2025-09-30 |
| Vanguard Group Inc | $394,722.00 | 10.38% | 2.08M | -13,088 | -0.63% | 2025-09-30 |
| Janus Henderson Group Plc | $198,166.00 | 5.21% | 1.04M | -18,356 | -1.73% | 2025-09-30 |
| Macquarie Group Ltd | $142,922.00 | 3.76% | 751,788 | -174,766 | -18.86% | 2025-09-30 |
| State Street Corp | $142,461.00 | 3.75% | 749,360 | -394 | -0.05% | 2025-09-30 |
| Congress Asset Management Co | $126,862.00 | 3.34% | 667,311 | +19,370 | +2.99% | 2025-09-30 |
| Chicago Capital, Llc | $108,099.00 | 2.84% | 568,611 | -3,214 | -0.56% | 2025-09-30 |
| Stephens Investment Management Group Llc | $105,424.00 | 2.77% | 554,542 | -50,271 | -8.31% | 2025-09-30 |
| Massachusetts Financial Services Co /Ma/ | $103,010.00 | 2.71% | 541,845 | +202,103 | +59.49% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $99,601.00 | 2.62% | 523,913 | -180,609 | -25.64% | 2025-09-30 |